p16INK4a Polyclonal antibody

p16INK4a Polyclonal Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

mouse, rat

Applications

WB, ELISA

Conjugate

Unconjugated

Cat no : 28416-1-AP

Synonyms

Arf, ARF INK4a, Cdkn2a, INK4a ARF, Ink4a/Arf, MTS1, p16, p16(INK4a), p16INK4a, Pctr1

---

Validation Data Gallery

• 

  WB analysis using 28416-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 28416-1-AP (Cdkn2a antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 28416-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 28416-1-AP (CDKN2A/p19ARF antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: NIH/3T3 cells, Neuro-2a cells, RAW 264.7 cells, C6 cells, mouse uterus tissue

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

28416-1-AP targets p16INK4a in WB, ELISA applications and shows reactivity with mouse, rat samples.

• Tested Reactivity: mouse, rat
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: p16INK4a fusion protein Ag28927
• Full Name: cyclin-dependent kinase inhibitor 2A
• Calculated Molecular Weight: 18 kDa
• Observed Molecular Weight: 19 kDa
• GenBank Accession Number: NM_001040654
• Gene Symbol: Cdkn2a
• Gene ID (NCBI): 12578
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Cdkn2a (cyclin-dependent kinase inhibitor 2a) is a cell cycle regulating gene encoding alternate proteins, p16Ink4a and p19Arf, that arrest the G1 phase through CDK4/6 inhibition. As they are tumor suppressors, p16Ink4a and p19Arf can be targeted for treatment of various cancers, including melanoma, cervical, and esophageal cancers.